The TRANSFORM-AF examine evaluated the influence of diabetes management-dose GLP-1 use for prevention of atrial fibrillation amongst sufferers with diabetes and weight problems.
Learn Healio’s in-depth protection of the TRANSFORM-AF trial.
The examine included 2,510 sufferers with diabetes, AF and weight problems throughout 170 VA hospitals. All sufferers had been assigned a GLP-1, DPP-IV inhibitor or sulfonylurea.
Over a median follow-up of three years, GLP-1 use was related to decrease danger for main secondary AF-related occasions vs. DPP-IV inhibition or sulfonylurea use.
The researchers reported observing the best profit in sufferers with a BMI higher than 40 kg/m2.
Weight reduction from GLP-1 use was reported to be modest.
Outcomes of the TRANSFORM-AF examine had been introduced at Coronary heart Rhythm 2025.
Learn Healio’s full protection of HRS 2025 right here.
Sources/Disclosures
Collapse
Selvaganesan P, et al. Late-breaking scientific trials and science: Medical trial updates and registries. Offered at: Coronary heart Rhythm 2025; April 24-27, 2025; San Diego.
